European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways

Descripción del proyecto

Una campaña multinivel para impulsar el cribado del cáncer colorrectal

En la Unión Europea (UE) se recomienda realizar un cribado de la población para detectar el cáncer colorrectal (CCR). A pesar de representar el 12,4 % de todas las muertes por cáncer, solo 1 de cada 7 ciudadanos de la UE participa en programas de cribado. El equipo del proyecto ONCOSCREEN, financiado con fondos europeos, pretende invertir esta tendencia fomentando la realización de pruebas de cribado precisas, no invasivas y rentables basadas en las nuevas tecnologías y en una mayor concienciación sobre la enfermedad. Asimismo, se requieren métodos de cribado personalizados que tengan en cuenta las variables genéticas y socioeconómicas, así como los factores de estrés ambiental. En este sentido, en el proyecto se desarrollará una metodología de estratificación poblacional del CCR basada en el riesgo para reflejar la prevalencia genética, el estatus socioeconómico y otros factores. El proyecto, que reúne a un consorcio de treinta y ocho socios, está en consonancia con la misión contra el cáncer de Horizonte Europa.

Objetivo

With Colorectal Cancer (CRC) being accountable for 12.4% of all deaths due to cancer, and with only 14% of EU citizens participating in screening programmes, there is an urgent need for accurate, non-invasive, cost-effective screening tests based on novel technologies and an increased awareness on the disease and its detection. Furthermore, personalized approaches for screening are needed, to consider genetic and other socioeconomic variables and environmental stressors that lead to different onsets of the disease. ONCOSCREEN responds to these challenges by developing a risk-based, population-level stratification methodology for CRC, to account for genetic prevalence, socio-economic status, and other factors. It complements this methodology by a) developing a set of novel, practical, and low-cost screening technologies with high sensitivity and specificity, b) leveraging AI to improve existing methodologies for CRC screening, allowing for the early detection of polyps and provision of a personalized risk status stratification, and c) providing a mobile app for self-monitoring and CRC awareness raising. Furthermore, ONCOSCREEN develops an Intelligent Analytics dashboard for policy makers facilitating effective policy making at regional and national levels. Through a multi-level campaign, the above-mentioned solutions are tested and validated. For the clinical solutions specifically, a clinical validation study has been planned with the participation of 4100 enrolled patients/citizens. To ensure the adoption of the developed solutions by the healthcare systems, their cost-effectiveness and financial viability will be assessed. The 48-months duration project will be implemented by a multidisciplinary consortium comprising of 38 partners, including technical solutions providers, hospitals, Ministries of Health as policy makers, legal and ethics experts, Insurance companies, involving actively end-users/citizens in all phases of implementation through targeted workshops. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening.

Programa(s)

Coordinador

EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINIS
Aportación neta de la UEn
€ 1 015 625,00
Dirección
THEANOUS 15
118 54 ATHENS
Grecia

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
Αττική Aττική Κεντρικός Τομέας Αθηνών
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 1 015 625,00

Participantes (39)